GeneTherapyLive’s Weekly Rewind – January 21, 2022

Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Around the Helix: Gene and Cell Therapy Company Updates - January 19, 2022

GeneTherapyLive’sAround the Helix is your chance to catch up with the latest news in gene and cell therapies, including partnerships, pipeline updates, and more. This week’s news includes updates from bluebird bio, Celularity, Gamida Cell, and more.

2. Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors. He discussed how the technology compares to other T-cell therapies.

3. Celularity’s CYNK-101 Wins Fast Track Designation for HER2+ Gastric/GEJ Cancers

The FDA has granted fast track designation to the natural killer cell therapy CYNK-101 in combination with standard frontline chemotherapy, trastuzumab (Herceptin), and pembrolizumab (Keytruda) for patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

4. Cilta-Cel's Efficacy in Heavily Pretreated Patients With Multiple Myeloma: Thomas G. Martin, MD

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from the CARTITUDE-1 study presented at ASH 2021. He discussed the positive results and cilta-cel's potential in this population.

5. The State of Gene and Cell Therapy for Sickle Cell Disease

Exciting new therapies for sickle cell disease are on the horizon. We explored some of the most promising investigational therapies in recognition of National Blood Donor Month. Read updates on lovo-cel, ARU-1801, CTX001 and others.